AKY-2519
Radiopharmaceutical
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: data expected in 2027 (NCT07581184; Aktis Oncology, Inc., 12 Nov 2026). “AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
BActinium-2 NCT07887971 · Metastatic Castration-Resistant Prostate Cancer Registry: NCT07887971 | 1 | Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 (Up to 30 days following last administration of [225Ac]Ac-AKY-2519); Part 1: Occurrence of dose-limiting toxicity (DLT) in participants (From first administration of [225Ac]Ac-AKY-2519 to the end of Cycle 1 (each cycle is 28 days)); Part 2: Objective Response Rate (ORR) (Up to 30 days following last administration of [225Ac]Ac-AKY-2519) 2028-12 | In progress: results expected 1 Dec 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| AKY-2519: this drug | Phase 1 | Radiopharmaceutical | B7-H3-targeted radioligand therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Elfetabart Drozuntecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Fluzoparib | Phase 3 | Small molecule | PARP (poly ADP-ribose polymerase), specifically PARP-1 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4357 | Phase 3 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mevrometostat | Phase 3 | Small molecule | EZH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Opevesostat | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Pasritamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Zadavotide Guraxetan | Phase 3 | Radioconjugate (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Luxdegalutamide | Phase 2 | Small molecule | Androgen receptor, Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-969 | Phase 1 | Undisclosed | PSMA / STEAP1 | not yet graded | No reviewed efficacy summary in this indication | |
| BPX-601 | Phase 1 | Cell therapy | PSCA | not yet graded | No reviewed efficacy summary in this indication | |
| RG6852 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow AKY-2519 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Company guidance: data expected in 2027 (Aktis Oncology, Inc., 12 Nov 2026). “AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.” Source ↗